CoLucid Pharmaceuticals

About:

CoLucid Pharmaceuticals is a biotechnology company focusing on therapies for central nervous system disorders.

Website: http://www.colucid.com

Twitter/X: lillypad

Top Investors: Domain Associates, TVM Capital Life Science, Novo Ventures, Care Capital, Pappas Ventures

Description:

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Total Funding Amount:

$97.3M

Headquarters Location:

Durham, North Carolina, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)colucid.com

Founders:

James F. White

Number of Employees:

1-10

Last Funding Date:

2015-01-13

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai